Dementia | Dementia Conference | Dementia Conferences | Alzheimers Conferences | Dementia conferences 2019| Tokyo | Japan| Asia pacific | USA | Europe | Middle East | 2018 | 2019

Quick Links

Abstract submission

Dementia congress 2019 abstract submission

sponsorship

Dementia congress 2019 sponsorship

DEMENTIA CONGRESS 2019

Theme: Exploring the Challenges and Excellence in Dementia Research

Dementia Congress 2019

Scientific Program

Dementia Congress 2019

After the successful completion of 12^th World Congress on Advances and Innovations in Dementia we take the opportunity to announce. Dementia congress 2019, 13^th World Congress on Advances and Innovations in Dementia, which is held during May 22-23, 2019 at Tokyo Japan. The main theme of our conference is "Exploring the Challenges and Excellence in Dementia Research" which covers wide range of critically important sessions. It’s a platform to bring all the neuroscientists together to share their experiences it’s the amalgam of scientific research as well as innovative ideas.

Neurological disorders are diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer's disease, brain tumours, epilepsy, Parkinson's disease, and stroke, dementia as well as less familiar ones such as front temporal dementia.

In the present day scenario a wide population of mankind are plagued by mental and neurological illnesses, with almost 165 million people or 38 percent of the population suffering each year from a brain disorder. With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden, it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year. An estimated 6.8 million people die every year as a result of neurological disorders.

Neurological disorders public health challenges describes and discusses the increasing global public health importance of common neurological disorders such as dementia, epilepsy, headache disorders, multiple sclerosis, neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, stroke and traumatic brain injuries.

National Alliance provided fund of $650 million to fuel the research on mental illness. NARSAD Young Investigator Grant provides $30,000 per year on research in Neural and behavior disorders such as dementia, schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. Brain tumor research receives less than 1% (0.7%) of national cancer research spending in the UK.

In order to accelerate the research in the field of Neuroscience Conference Series organizes different conference series worldwide.

About Organization

3000+ Global Events
25 Million+ Visitors
25000+ unique visitors per conference
70000+ page views for every individual conference
Unique Opportunity! Online visibility to the Speakers and Experts

Highlights:

Dementia	Vascular Dementia
Alzheimers disease	Neurodegenerative Diseases
Brain diseases	Animal Models in Dementia
Amyloid protein in dementia	Diagnosis of Dementia
Nursing care in Dementia	Dementia Management
Drug Development in Dementia	Recent Advancement in Treatments of Dementia
Clinical Trials & Case Reports in Dementia	Aging and Progressive dementia

Who should attend?

Neuroscientist
Neuroanatomist
Neurobiologist
Neurochemist
Neurological Surgeon
Neurologist
Neuropathology’s
Neuropharmacologist
Neurophysiologist
Neuropsychologist
Neuroradiology’s
psych biologist
Biological Psychologist
Psychiatrist
Neuroscience Nurse
Psychophysicist
Professors
Students
Neuro drug Manufacturers

Benefits of attending:

Networking Opportunities
Grow Your Professional Network
Build Your Knowledge Base
Expand Your Resources
Meet Experts & Influencers Face to Face
Learning In a New Space
Break Out of Your Comfort Zone
New Tips & Tactics
Greater Focus
The Serendipity of the Random Workshop

Who should sponsor/exhibit:

Pharmaceuticals
Drug Manufacturers
Hospitals
Educational Institutes
Research Centres
Hospitals
Associations
Societies

Track 1: Dementia

Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Other common symptoms include emotional problems, problems with language, and a decrease in motivation. A person's consciousness is usually not affected. A dementia results in a change from a person's usual mental functioning and a greater decline than one would expect due to aging. These diseases also have a significant effect on a person's caregivers.

15th International Conference on Dementia and Alzheimers Disease March 25-26, 2019 Osaka, Japan |11th International Conference on Vascular Dementia February 15-16, 2019,Amsterdam |11th World Congress on Alzheimers Disease & Dementia March 20-21, 2019 Sydney, Australia |12th International Conference on Alzheimer’s Disease & Dementia October 29-31, 2018 Valencia, Spain |12th World Congress on Dementia and Alzheimer Rehabilitation April 11-12, 2019 Stockholm, Sweden |14th World Summit on Alzheimer’s Disease, Dementia Care Research and Awareness August 31-September 01, 2018 Boston, USA|13th Annual Conference on Dementia and Alzheimers Disease December 13-15, 2018 Abu Dhabi, UAE |2nd International Conference on Dementia and Dementia Care April 15 -16, 2019 Toronto, Canada | 10th International Conference on Dementia and Dementia Care July 23-24, 2019 Rome, Italy | 13th World Congress on Dementia and Alzheimer's Disease March 25-26, 2019 Melbourne, Australia |13th World Congress on Alzheimers and Dementia December 06-07, 2018 Amsterdam, Netherlands |15th International Conference and Exhibition on Alzheimers Disease, Dementia & Ageing April 22-23, 2019 Rome, Italy | 12th World Congress on Dementia and Alzheimer Rehabilitation November 27-29, 2018 Athens, Greece|Global Alzheimer’s disease, Dementia and Ageing Awareness July 17-18, 2019 Zurich, Switzerland

Related Societies & associations:

The Alzheimer’s association, Dementia society of America, Alzheimer's society, lewy body dementia association, Dementia uk, Alzheimer Scotland, Alzheimers.net, Alzheimer's Australia, National council of certified dementia practioners, The Alzheimer’s disease association (ada) , The Malta dementia society

Track 2: Alzheimers disease

Alzheimers disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia. The most common early symptom is difficulty in remembering recent events short-term memory loss. [As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death.

Related Societies & associations:

Track 3: Vascular Dementia

Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. This death of brain cells can cause problems with memory, thinking or reasoning. Together these three elements are known as cognition. When these cognitive problems are bad enough to have a significant impact on daily life, this is known as vascular dementia.

Related Societies & associations:

Track 4: Frontotemporal dementia

Frontotemporal dementia is an uncommon type of dementia that mainly affects the front and sides of the brain (frontal and temporal lobes) and causes problems with behaviour and language. Dementia mostly affects people over 65, but front temporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, Frontotemporal dementia tends to develop slowly and get gradually worse over several years. Frontotemporal dementia is misdiagnosed as a psychiatric problem or as Alzheimer's disease.

Related Societies & associations:

Track 5: Neurodegenerative Diseases

Neurodegenerative diseases cause your brain and nerves to deteriorate over time. They can change your personality and cause confusion. They can also destroy your brain’s tissue and nerves. Some brain diseases, such as Alzheimer’s disease, may develop as you age. They can slowly impair your memory and thought processes. Other diseases, such as Tay-Sachs disease, are genetic and begin at an early age.

Related Societies & associations:

Track 6: Brain diseases

The brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic injury.

Related Societies & associations:

Track 7: Parkinson’s diseases

Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Related Societies & associations:

Track 8: Anxiety & Depression

Apathy, depression and anxiety are common conditions experienced by people with dementia. They are known as psychological conditions because they can affect a person’s emotional and mental health. Anxiety is more than just feeling stressed or worried. Anxious feelings are a normal reaction to a situation where a person feels under pressure and usually pass once the stressful situation has passed, or the ‘stressor’ is removed. Depression affects how a person feels about themselves. A person may lose interest in work, hobbies and doing things he or she normally enjoys. Some people may lack energy, have difficulty sleeping or sleep more than usual, while some people feel anxious or irritable and find it hard to concentrate.

Related Societies & associations:

Track 9: Animal Models in Dementia

Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development have been carried out. Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development has been carried out.

Related Societies & associations:

Track 10: Amyloid protein in dementia

Amyloid Plaques One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP)

Related Societies & associations:

Track 11: Diagnosis of dementia

Diagnosing dementia and determining what type it is can be challenging. A diagnosis of dementia requires that at least two core mental functions be impaired enough to interfere with daily living. They are memory, language skills, ability to focus and pay attention, ability to reason, solve problem and visual perception

Related Societies & associations:

Track 12: Nursing care in Dementia

Nurses provide the specialist dementia support that families need. When things get challenging or difficult, our nurses work alongside people with dementia, and their families: giving them one-to-one support, expert guidance and practical solutions.

Related Societies & associations:

Track 13: Dementia Management

There is no cure for dementia, so the chief goals of treatment are to:

a. Maintains quality of life

b. Enhances cognition, mood and behaviour

c. Fosters a safe environment

d. Promotes social engagement

Related Societies & associations:

Track 14: Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Related Societies & associations:

Track 15: Recent Advancement in Treatments of Dementia

Epidemiological studies show that, worldwide, the number of people aged over 65 will increase substantially in the next decades and that a considerable proportion of this population will develop dementia. Ample evidence shows that ageing is associated with a high rate of painful conditions, irrespective of cognitive status. The number of patients with dementia who will experience painful conditions is therefore likely to increase.

Related Societies & associations:

Track 16: Clinical Trials & Case Reports in Dementia

The goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.

Related Societies & associations:

Theme: Exploring the Challenges and Excellence in Dementia Research

Dementia congress 2019 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the“13^th World Congress on Advances and Innovations in Dementia” which is going to be held during May 22-23, 2019 Tokyo, Japan.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2019 organizing committee look forward to meeting you in Tokyo, Japan.

For more details please visit - http://dementiacongress.neurologyconference.com

Why in Japan?

With one in five elderly Japanese predicted to have dementia by 2025, entire communities are working to improve the lives of older citizens and more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This numbers will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.

Major Neuroscience Societies and Associations in Tokyo:

World Federation of Neurology	Japanese Society of Child Neurology
Neurospinal Society of Japan	Cognitive Neuroscience Group

Major Dementia and Alzheimer’s Societies and Associations around Globe:

Alzheimer's Australia	Hilarescere Foundation in Italy
Alzheimer Society of Bangladesh	Alzheimer Support Group
Alzheimer's Association	Southern Clinical Neurological Society
American Academy of Neurology	ESNR European Society of Neuroradiology
European Neurological Societies	Alzheimer Austria
Foundation Alzheimer Aruba (FAA)	Alzheimer's disease Chinese
Spanish Society of Neurology	Alzheimer's Society
Major Neurological Associations in Italy	British brain tumor association

Top Neuroscience Universities in Japan

Aino University	Osaka Kawasaki Rehabilitation University
Hagoromo International University	Osaka University of Human Sciences
Hannan University	Soai University
Heian Jogakuin-St. Agnes'-University	Tokiwakai Gakuen University
Kansai Medical University	Osaka University
Kinki University	Okinawa Institute of Science and Technology
Kwansei Gakuin University, Osaka-Umeda	Keio University
Morinomiya University of Medical Sciences	Nagoya University

Top Neuroscience Universities in Globe:

Dalhousie University	University of Nottingham
Leiden University	Cardiff University
Temple University USA	University of Toronto
University Oklahoma	University Sheffield
University of Bristol	University California
Florida International University	University of Amsterdam
University of Edinburgh	Karolinska Institute
University of Milan	University of Gothenburg

Hospital Associated with Neuroscience:

Osaka University Hospital	Tokyo metropolitan neurological hospital
Kosei Nenkin Hospital	Shonan kamakura general hospital
Sumitomo Hospital	Jikei university school of medicine hospital
Yodogawa Christian Hospital	Yamaguchi university hospital
Wada Hospital	The university of tokyo hospital
Ueda Surgery Hospital	St. luke's international hospital
Osaka University Hospital	Japan bangladesh friendship hospital
Kosei Nenkin Hospital	Tokyo metropolitan neurological hospital

Companies Associated with Neuroscience in Japan

Pfizer	Forest Laboratories
GlaxoSmithKline	Eli Lilly
Solvay of Belgium	Wyeth Pharmaceuticals
Fujisawa Pharmaceutical	Organon International
Meiji Seika	Lund beck
Janssen Pharmaceutical	Asahi Kasei Corporation

Top Neuroscience Companies:

Brainomix	Polyneuron Pharmaceuticals AG Corp.
reHaptix GmbH	Biogen Idec
KB Medical	Intento SA
OncoVision	AcelRx Pharmaceuticals, Inc.
Trevena	AcelRx Pharmaceuticals, Inc.
Mintlabs	Mylan
Actavis	Bayer
Lundbeck	Novartis

Glance at market of dementia:-

There were an expected 46.8 million individuals overall living with dementia in 2015 and this number is accepted to be near 50 million individuals in 2017. This number will twofold at regular intervals, achieving 75 million out of 2030 and 131.5 million out of 2050. A great part of the expansion will be in creating nations. Officially 58% of individuals with dementia live in low and center pay nations, yet by 2050 this will ascend to 68%. The quickest development in the elderly populace is occurring in China, India, and their south Asian and western Pacific neighbors. The evaluated for the aggregate number of dementia sufferers worldwide in the years 2015, 2030 and 2050. It is evaluated that there will be around 75 million individuals experiencing dementia in 2030.

Statistic maturing is an overall procedure that demonstrates the achievements of enhanced human services in the course of the most recent century. Many are presently living longer and more beneficial lives thus the total populace has a more noteworthy extent of more seasoned individuals. Dementia principally influences more seasoned individuals, in spite of the fact that there is a developing familiarity with cases that begin before the age of 65. There are more than 9.9 million new instances of dementia every year around the world, inferring one new case at regular intervals.

The World Alzheimer Report 2015 updates ADI's worldwide assessments of the predominance, occurrence and expenses of dementia in view of efficient surveys. The report makes key suggestions to give a worldwide structure to activity on dementia. The report likewise incorporates a survey of the proof for and against late patterns in the predominance and frequency of dementia after some time, and in addition an examination of the more extensive societal effect of dementia. The aggregate assessed overall expense of dementia is US$818 billion of every 2015, which speaks to 1.09% of worldwide GDP. By 2018, the worldwide expense of dementia will transcend a US$ trillion.

Coordinate therapeutic consideration costs represent around 20% of worldwide dementia costs, while coordinate social area costs and casual consideration costs each record for about 40%. The relative commitment of casual consideration is most prominent in the African areas and least in North America, Western Europe and some South American districts, while the turnaround is valid for social part costs. This implies if worldwide dementia care were a nation, it would be the eighteenth biggest economy on the planet.

Some products manufactured by the industry related Neuroscience Research:-

NeuroScience ImmuWell.
NeuroScience AdreCor.
NeuroScience Calm CP.
Kavinace .
Purified anti-β-Dystroglycan Antibody.
Alexa Fluor® 594 anti-Neurofilament H (NF-H), Phosphorylated Antibody.
Mouse & Rat Spinal Cord Matrices.
Surgical & Dissection Tools.

Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

References:

http://www.alzheimers.org.uk/dementiauk

https://en.wikipedia.org/wiki/Alzheimer's_Research_UK

http://www.alzheimersresearchuk.org/

http://www.alz.org/uk/dementia-alzheimers-uk.asp

http://www.alzheimersresearchuk.org/about-dementia/facts-stats/

http://www.alz.org/research/funding/alzheimers_our_commitment.asp

https://www.ucl.ac.uk/dementia

http://www.city.ac.uk/courses/cpd/evidence-based-dementia-care

http://www.kcl.ac.uk/ioppn/depts/oldage/research/bdr.aspx

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	May 22-23, 2019
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

13^th World Congress on Advances and Innovations in Dementia May 22-23, 2019 Tokyo, Japan

Recommended Global Neuroscience Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Abstract submission

sponsorship

Dementia Congress 2019

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues